Journal
CURRENT OPINION IN ORGAN TRANSPLANTATION
Volume 19, Issue 1, Pages 47-53Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOT.0000000000000035
Keywords
clinical studies; kidney transplantation; macrophages; mesenchymal stromal cells; transplantation tolerance
Categories
Funding
- Fondazione ART per la Ricerca sui Trapianti (Milan, Italy)
Ask authors/readers for more resources
Purpose of reviewCell therapy with mesenchymal stromal cells (MSC) has emerged as a promising tolerance-inducing strategy, as MSC are potent modifiers of immune cells within adaptive as well as innate arm of the immune system. Here, we review recent evidence on both the beneficial and deleterious effect of MSC in experimental models of solid organ transplantation as well as first clinical experiences of MSC therapy in kidney transplant recipients.Recent findingsMSC are able to reprogram macrophages toward an anti-inflammatory phenotype capable to regulate antigraft immune response. This interaction is mediated mainly by TNF--induced-protein-6. Conversely, MSC also take on a proinflammatory phenotype and actually could worsen graft outcome. MSC in clinical transplantation is in its infancy and nobody so far has attempted to or provided evidence that this cell-based therapy is capable to promote operational tolerance. There are, however, supporting data of the ex-vivo immunoregulatory activity of MSC in treated patients.SummaryMSC have a great potential as a tolerance-promoting cell therapy. Extensive investigations are still needed to dissect the mechanism(s) of action of MSC, particularly in the setting of a proinflammatory environment, and to establish specific assays for monitoring MSC-treated patients to define the protolerogenic potential of MSC-based therapy in kidney transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available